Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 190 results for "Tecfidera Treated Patients"

Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany

Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Ger...

Tecfidera® is a product containing dimethyl fumarate (DMF) as the active ingredient for the treatment of MS. It was approved by the European Commission in January 2014. Worldwide sales of Tecfidera® as reported by Biogen Idec for the previous 4 ..., 4 days ago
European Medicines Agency

Inform Patients of PML Case With Tecfidera in MS

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is advising physicians to inform their patients about a fatal case of progressive multifocal leukoencephalopathy (PML) in a patient being treated with dimethyl ...
 Medscape2 weeks ago News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014  European Medicines Agency1 day ago Highlights of EMA Pharmacovigilance unit meeting  Pharma Letter1 week ago

Biogen Falls On Patient's Death

Biogen stock traded down 5% yesterday following the announcement that a patient administered with Tecfidera, the company's MS drug, died after developing a brain infection Page 1 of 2 Click Ticker to See live coverage Biogen Idec Inc ( ...
 Bidness Etc4 weeks ago Hot Biogen shares fall after Tecfidera patient dies  CNBC1 month ago Biogen falls after Tecfidera patient dies  CNBC1 month ago

Biogen Falls After Patient Taking Top-Selling Tecfidera Dies

(Updates with closing shares in third paragraph.) Oct. 22 (Bloomberg) -- Shares of Biogen Idec Inc. fell the most in seven months after the company said a patient developed a rare brain infection and died while taking its top-selling multiple ...
 Washington Post1 month ago Health Exchange: Biogen shares drop on Tecfidera patient death  Austin American Statesman1 month ago Biogen Falls After Patient on Top-Selling Drug Dies  BusinessWeek1 month ago Why Biogen Idec Stock Shares Are Getting Pummeled Today  Nasdaq1 month ago
Boston Globe

Biogen Idec prices new multiple sclerosis treatment at $62,036 per year

Cambridge biotech Biogen Idec Inc. said Friday it will charge $62,036 per patient for a year's treatment with its newly approved multiple sclerosis drug Plegridy. The list price of Plegridy, a new type of injectable drug that treats adults with the ...
 Boston Globe1 month ago Biogen Idec Announces Strides In Clinical Studies For MS Treatments  Bioresearch Online2 months ago Biogen Idec announces encouraging data from Phase III multiple sclerosis study  Individual.com2 months ago
Bidness Etc

Why Has Biogen (BIIB) Stock Been Trading Down?

Biogen stock has been falling due to patent issues and negative sentiments regarding the death of a patient who had been using Tecfidera. However, the company's pipeline drugs show potential Page 1 of 2 Click Ticker to See live coverage ...
 Bidness Etc21 hours ago EMA review for Biogen Idec's haemophilia A therapy  Pharmafocus2 weeks ago Company Update (NASDAQ:BIIB): Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA (rFVIIIFc) Marketing Authorization Application for Review  Jutia Group3 weeks ago Is Biogen Idec Inc. in Trouble?  Motley Fool3 weeks ago

Forward Strides For Forward Pharma At Its IPO

Summary FWP, a Danish biopharmaceutical firm focused on treatments for multiple sclerosis (MS), plans have its IPO this week. FWP will offer 9,523,810 shares at an expected price range of $20 to $22; lead underwriters are Jeffries LLC, Leerink ...
 Seeking Alpha1 month ago IPO Preview: Forward Pharma A/S  Seeking Alpha1 month ago IPO Report: Forward Pharma A/S (FWP)  Equities.com1 month ago

Biogen Decline Over PML Tied To Tecfidera, Offers Investors A Lower Entry Point

Summary Biogen reported strong Q3 earnings. While the stock price has risen over 24% in the last year, the valuation still looks reasonable. Analysts have raised their earnings estimates 6.1% this year and 3.4% next year. Biogen is up more than ...
 Seeking Alpha3 weeks ago Why Biogen Stock Is Still An Investment Opportunity  Seeking Alpha2 months ago

Multiple Sclerosis Drugs Could Transform Market Again

Over the last four years, life for multiple-sclerosis patients has changed for the better as a new generation of powerful oral drugs has moved into a market dominated by injectables. But things aren't done changing yet, as a September conference ...
 Investor's Business Daily1 month ago

Royalty Pharma announces $3.3 bn royalty transaction with CFFT

Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion. ...
 PharmaBiz1 day ago Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics  Citybizlist3 days ago Royalty Pharma : Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics  4 Traders3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less